ABSTRACT Synthetic a-human atrial natriuretic polypeptide was infused in patients with congestive heart failure (CHF) (New York Heart Association class III or IV) and in those without CHF. The infusion of atrial natriuretic polypeptide (ANP) at a rate of 0. 1 gg/kg/min significantly decreased pulmonary capillary wedge pressure and increased stroke volume index in all of the patients with CHF, whereas it decreased pulmonary capillary wedge pressure but caused no significant change in stroke volume index in the patients without CHF. Concomitant significant reductions in total systemic resistance were observed in both groups of patients. The ANP infusion significantly increased the urine volume, the excretion of sodium, and endogenous creatinine clearance in the patients without CHF. In the patients with CHF, it also showed a tendency to increase all these variables, but the urine volume did not correlate with the reduction in pulmonary capillary wedge pressure. The ANP infusion also decreased plasma aldosterone concentrations in these patients, although no significant difference was observed in the decrement of the plasma aldosterone concentration in the patients with and those without CHF. These findings indicate that the ANP infusion improves left ventricular function in patients with CHF, and suggest that this improvement results mainly from the vasodilating activity of ANP.
To clarify whether or not ANP is clinically useful for the treatment of CHF, we have examined the effects of the continuous infusion of a-human ANP on the left ventricular, renal, and endocrine functions in patients with CHF and compared them with those functions in patients without CHF.
Methods
Patients. Six patients with clinically overt CHF (New York Heart Association [NYHA] class III or IV) and six patients without CHF participated in this study. There were 10 men and two women ranging in age from 32 to 70 years (mean + SE 51 + 3). The cause of CHF was dilated cardiomyopathy in four, aortic regurgitation in one, and hypertensive heart failure in one. In all patients with CHF a Swan-Ganz catheter was inserted for therapeutic use at bedside. Five of the six patients without CHF underwent diagnostic cardiac catheterization (because of old myocardial infarction in two, suspicion of angina pectoris in three) and a Swan-Ganz catheter was inserted in the remaining patient as part of the treatment of acute myocardial infarction. One patient with CHF and two patients without CHF had not been treated. Five patients with CHF were receiving drugs, including diuretics and cardiac glycosides. Four patients without CHF had been receiving coronary vasodilators. All vasodilators, diuretics, and inotropic agents were discontinued at least 24 hr before the study. Informed consent was obtained from each patient. This study was approved by the ethical committee on human research of Kyoto University (No. .
Synthetic a-human ANP. a-Human ANP (human ANF 99-126) was synthesized as previously described.3 10 The homogeneity of the a-human ANP used in this study was confirmed by reverse-phase, high-performance liquid chromatography and amino acid analysis. The a-human ANP was dissolved in saline with 10% lactose and was sterilized by passage through a 0.22 gm Millipore filter (Bedford, MA). The chemical nature and content of the a-human ANP in vials were verified by high-performance liquid chromatography and radioimmunoassay (RIA), as reported elsewhere 37 Study protocol. After 30 min of bed rest, two serial baseline measurements were obtained in each subject at an interval of 15 min and then the ANP infusion was begun at a rate of 0.1 ,ug/kg/min for 30 min through a peripheral vein with the use of an infusion pump (Nipro SP-50, Nipro Co., Ltd., Osaka, Japan) with a flow rate of 0.4 ml/min. Hemodynamic measurements and collections of blood and urine samples were performed as summarized in figure 1. These investigations were carried out before the arteriograms and ventriculograms.
Hemodynamic measurements. Pulmonary capillary wedge pressure, pulmonary arterial pressure, and right atrial pressure were determined with a Swan-Ganz catheter ( Measurements of the plasma hormones. The plasma ANP concentration was measured by a specific RIA for a-ANP reported previously.9 31 32 Briefly, this RIA recognizes a carboxyterminal fragment of ANP, a-ANP (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) , and the minimal detectable quantity of a-human ANP is 1 pg/tube. Plasma renin activity and the plasma aldosterone concentration were measured with commercially available kits, Renin RIA beads (Dainabot Co., Ltd., Tokyo, Japan) and Aldosterone Test Shionogi (Shionogi Co., Ltd., Osaka, Japan), which are based on previously reported methods.33 3 Plasma norepinephrine and epinephrine levels were measured by high-performance liquid chromatography combined with the trihydroxyindole fluorometric procedure. 35 36 Other biochemical measurements. The sodium, potassium, and chloride concentrations in serum and urine were measured by the ion electrode method (Hitachi 736, Hitachi Medical Corporation, Tokyo, Japan). Serum and urine osmolarities were determined by the freezing point depression (Auto stat OM-6010 Kyotodaiichikagaku Co., Ltd., Kyoto, Japan). Serum and urine creatine concentrations were determined by Jaffe's proce-dure (Hitachi 736, Hitachi Medical Corporation, Tokyo, Japan 
Results
The plasma ANP concentration. The time course of the plasma ANP concentration in each individual patient in this study is summarized in table 1. Plasma ANP concentrations before the ANP infusion were significantly higher in the patients with CHF than in those without CHF (1490 + 459 vs 161 ± 44 pg/ml, p < .05). Plasma ANP levels promptly increased, reaching a peak at 15 min after the start of the ANP infusion, and returned to the preinfusion level at 15 min after the end of the infusion in the patients with CHF. In those without CHF, plasma ANP levels were the highest at 30 min of the infusion period and gradually decreased during the 30 min postinfusion period.
Hemodynamic effects of ANP. Five of the six patients with CHF showed a marked reduction in pulmonary capillary wedge pressure of 10 mm Hg or greater and an increase in stroke volume index of 25% or greater during the ANP infusion. The remaining patient (No. 6), whose stroke volume index was the highest, showed a reduction in pulmonary capillary wedge pressure of 4 mm Hg and an increase in stroke volume index of 5%. On the other hand, the ANP infusion decreased pulmonary capillary wedge pressure by 2 to 9 mm Hg in the patients without CHF, but it resulted in no significant change in stroke volume index in these patients. The mean hemodynamic responses to the ANP infusion in the patients with and without CHF are presented in figures 2, 3, and 4. As presented in figure  2 , A, pulmonary capillary wedge pressure began to decline within 5 min and a significant response occurred within 15 to 25 min and was sustained for 25 to 30 min after the end of the ANP infusion in both groups of patients, although the change was greater in the patients with CHF than in those without it. The infusion of ANP produced a change in right atrial pressure (figure 2, B) similar to that in pulmonary capillary wedge pressure in both groups of patients. Mean pulmonary arterial pressure also significantly decreased during the infusion of ANP (from 38.9 ± 3.2 to 29.8 ± 4.3 mm Hg) in the patients with CHF and decreased from 12.0 ± 1.5 to 8.5 ± 1.1 mm Hg in the patients without CHF. In the patients with CHF, mean arterial pressure fell slightly but significantly without a concomitant increase in heart rate, whereas it decreased by about 10 mm Hg in the patients without . In the patients without CHF, total systemic resistance also fell significantly during the infusion of ANP and returned to the control value within 15 min after the end of the infusion ( figure 4, B) ; total pulmonary resistance tended to decrease. Figure 5 shows effects of the infusion of ANP on the relationship between pulmonary capillary wedge pressure and stroke volume index. In the patients with CHF, all plots significantly moved upward and to the left, indicating an improvement in left ventricular function. In the patients without CHF, however, the CHF, with a concomitant significant increase in heart rate (figure 3).
Stroke volume index increased significantly to 31. a control value of 321.7 ± 84 to 268.3 ± 57.9 pg/ml at 30 min and to 235.0 ± 45.1 pg/ml at 60 min in the patients with CHF, whereas a significant increase in the plasma norepinephrine concentration was observed at 15 and 30 min in the patients without CHF. The infusion of ANP produced no significant change in the plasma epinephrine concentration in these patients.
Other biochemical findings. The serum sodium, potassium, and chloride concentrations did not change during or after ANP. The ANP infusion did not affect the concentrations of SGOT, SGPT, alkaline phosphatase, lactate dehydrogenase, y-glutamyl transpeptidase, creatinine, nor blood urea nitrogen. There were no significant changes in red blood cell, white blood cell, or platelet counts between before and after the ANP infusion.
Discussion a-Human ANP is a cardiac hormone secreted through the coronary sinus from the heart9 14 and has potent vasodilating and diuretic activities.10 14-21 Since vasodilators and diuretics have been widely used to treat severe CHF, the infusion of ANP would be expected to produce beneficial effects on left ventricular function of the failing heart. The present study demonstrates that the ANP infusion increases stroke volume index and decreases pulmonary capillary wedge pressure in patients with CHF, indicating that the infusion of ANP improves left ventricular function of the failing heart, as defined by a shift upward and to the left on the left ventricular function-curve plot (figure 5). These results are consistent with the recent studies described by Riegger et al. 28 patients without CHF experienced excessive hypotension. It therefore should be noted that ANP has a more beneficial effect on left ventricular function in patients with CHF than in those without CHF. In the present study, no significant difference in the plasma ANP concentration during the infusion of the drug was observed between the patients with and without CHF, and the plasma ANP concentration during the ANP infusion did not correlate with the maximal change either in pulmonary capillary wedge pressure or in stroke volume index. It is therefore unlikely that the difference observed in hemodynamic responses between the patients with and without CHF resulted from differences in the plasma ANP concentration during its infusion. The hemodynamic results observed in this study are compatible with the established concept that conventional balanced vasodilators produce a greater improvement in left ventricular function of the failing heart than in the normal heart.4-' Riegger et al.28 also studied the effects of the infusion of ANP in four patients with CHF but did not compare them with effects in patients without heart failure.
In the present study, patients with CHF had much higher plasma ANP levels than those without CHF before the ANP infusion, confirming the previous observations that the plasma ANP concentration shows a graded rise in patients with CHF.2127 Nevertheless, an improvement in left ventricular function was brought about by the infusion of ANP in such patients with high plasma ANP levels in the present study. This indicates that the additional administration of ANP is effective in patients with CHF. Although the exact mechanism responsible for the beneficial effects of ANP is not clear at present, this may be explained in part by the large distribution volume of a-human ANP. In addition to its vasodilator activity, ANP has diuretic and natriuretic activities. A volume contraction due to these activities would contribute to a reduction in the preload. In the present study, the patients with CHF showed only a tendency to increased urine volume and excretion of sodium during the peptide infusion, although significant diuretic and natriuretic responses were observed in the patients without CHF. In addition, no significant correlation was observed between the urine volume and the reduction in pulmonary capillary wedge pressure during the infusion in the patients with CHF. Thus, these findings indicate that the renal effects of ANP on a decrease in the preload are not major components in improving left ventricular function in the patients with CHF. However, one patient with CHF experienced substantial diuresis (530 ml/30 min) during the infusion of ANP (indicated by an asterisk in figure 5 ), and the reduction in pulmonary capillary wedge pressure in this patient was the greatest in our study group (from 26 to 5 mm Hg). This observation suggests that a more prominent decline in the preload can be anticipated as a result of the combined vasodilating and diuretic effects of ANP. The blunted diuresis observed in the patients with CHF might be attributable to the effect of furosemide in five patients, since they took it until 24 hr before the study, and to decreased renal function in two patients. However, since Scriven and This study shows that the plasma norepinephrine level tends to decrease during the infusion of ANP in patients with CHF. This decrement in the plasma norepinephrine level may reflect sympathetic withdrawal due to the improvement in left ventricular function in these patients. In the patients without CHF the plasma norepinephrine level rose in parallel with a fall in blood pressure. This rise in the plasma norepinephrine level may be accounted for by an arterial baroreceptormediated increase in sympathetic nerve activity. The augmented cardiac output without a significant increase in stroke volume in the patients without CHF in the present study can be explained by an increased heart rate due to sympathetic activation.
In conclusion, the infusion of ANP improves left ventricular function in patients with CHF and this beneficial effect seems to result from the vasodilating activity of ANP rather than its diuretic activity or its inhibitory activity on the aldosterone secretion. Since ANP has the great advantage of being an endogenous substance, further large-scale blinded studies are necessary to confirm its usefulness for the treatment of patients with CHF.
We thank Dr. N. Morii 
